Cidara Therapeutics Inc. (San Diego), Rights offering, 6.6S, $30.00, 2/14/20. Cocrystal Onxeo SA (Paris), Private placement, N/A, $8.20, 6/9/20. Outlook

2019-05-21

Klik her for at følge aktiekursen i realtid Onxeo Clinical results update Green light for Ph Ib/II after DRIIV-1 interim data Price €0.89 Market cap €46m Net cash (€m) at end Q318 13.0 Shares in issue 52.8m Free float 80% Code ONXEO Primary exchange Euronext Paris Secondary exchange OMX Copenhagen Share price performance % 1m 3m 12m Abs 0.1 (24.4) (23.2) Quick definitions from WordNet (rights issue) noun: an offering of common stock to existing shareholders who hold subscription rights or pre-emptive rights that entitle them to buy newly issued shares at a discount from the price at which they will be offered to the public later 2021-04-09 Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million) Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, 16 timmar sedan · Onxeo Launches a Rights Issue to Accelerate Its R&D Programs. Businesswire 34d: Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results. Onxeo Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to 100% The fund raising proposed by Onxeo is a capital increase through the issuance of New Shares with preferential subscription rights (PSR). Prior to the proposed transaction, Onxeo's share capital Onxeo : Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to ONXEO : Launches a Rights Issue to Accelerate Its R&D Programs: BU. 02/05: ONXEO S A Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares.

ISIN. FR0010095596 Market. Euronext. Symbol.

Onxeo Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to 100%

Clients Onxeo SA. Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares. 2014-11-18 2014-11-18 2021-03-10 2014-11-18 2021-03-11 Due to the rights issue that is ongoing until March 31, 2021, the publication of the 2020 annual results will take place on April 21, 2021 after market close and the annual general meeting will be 4 hours ago Onxeo has turned to the public markets for cash to fuel its research and development ambitions, starting a rights issue in a bid to raise up to €41.6 million ($52.2 million). The Franco-Danish biotech plans to use the cash to expand a Phase III study of its liver cancer drug and prepare to advance its severe oral mucositis candidate into late-stage trials. 4 hours ago 4 hours ago These issues shall be notified on the Onxeo website (Investors section / Regulated information / Total number of voting rights and shares comprising the share capital).

Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million) 11/17/2014 09/04/2019 Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development […]

Klicka här för att följa aktiekursen i realtid A rights issue or rights offer is a dividend of subscription rights to buy additional securities in a company made to the company's existing security holders. When the rights are for equity securities, such as shares, in a public company, it is a non-dilutive(can be dilutive) pro rata way to raise capital.Rights issues are typically sold via a prospectus or prospectus supplement.

Reading through this list alone will already add to the impression readers may get from how Rights Issues are processed. Use the toggles to open the text.
Mcdonalds arbetare

The number of shares may be increased to 9,246,098 new shares if the extension clause is fully exercised and all the financial 2021-03-16 · RIGHTS ISSUE: 1 new share @ 0.71 EUR for 6 existing shares 09/04 EN DIRECT DES MARCHES : Michelin, Suez, Airbus, Dassault, Bénéteau, Cellectis Onxeo Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to 100% This rights issue will allow us to pursue this step-up, by accelerating and expanding development programs which are the base of ONXEO value. » (Judith Greciet, CEO of ONXEO). Rights issue main terms This capital increase with shareholder preferential subscription rights will result in the issuance of Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage 16 timmar sedan · Zeit Aktuelle Nachrichten; 13:51: Onxeo S.A.: Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised: This transaction will accelerate the development of the Company and its 4 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Bioalliance PharmaAct Nom Cat-P Aktie [Valor: 1884147 / ISIN: FR0010095596] Kaufen Verkaufen 16 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Regulatory News: Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada 1 month Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Business Insider